AAPM&R Now Recommends PRP for Knee Osteoarthritis: What This Means for Patients

On April 16, 2026, the American Academy of Physical Medicine and Rehabilitation (AAPM&R) — one of the largest physiatry organizations in the United States, representing approximately 10,000 physician members — released a new clinical guidance statement on the use of platelet-rich plasma (PRP) for knee osteoarthritis. The recommendation is clear: PRP should be considered for patients with mild to moderate knee osteoarthritis (Kellgren-Lawrence grades I–III) who remain symptomatic despite adequate conservative management, including physical therapy, NSAIDs, and activity modification.

This is not a small development. For years, PRP has occupied a gray area in musculoskeletal medicine — promising data, but no formal endorsement from a major medical society. That has now changed. As a physician who has been using PRP in my practice for over a decade, I can tell you that this guidance represents a significant shift in the standard of care. It moves PRP from "promising but unproven" to "recommended by a major medical society." And for patients who have been told their only options are cortisone injections or waiting for a knee replacement, this changes the conversation entirely.

What the AAPM&R Guidance Actually Says

The guidance statement, published in the PM&R journal, was developed by a multidisciplinary panel of experts who systematically reviewed the available evidence. Their key recommendation is that PRP be offered to patients with symptomatic knee osteoarthritis of Kellgren-Lawrence grades I, II, or III who have not achieved adequate relief from first-line conservative treatments. The panel specifically notes that PRP is not recommended for severe (grade IV) osteoarthritis, where joint space narrowing and bone-on-bone contact limit the potential for meaningful improvement.

This aligns precisely with how I evaluate patients in my practice. When a patient comes to me with knee pain and imaging shows mild to moderate degenerative changes, I perform a thorough biomechanical assessment — including osteopathic manipulative treatment to address joint restrictions and muscle imbalances — before considering any injection. If conservative measures have been exhausted and the patient remains symptomatic, PRP is often the next logical step. For a detailed explanation of how PRP works, how it compares to cortisone, and how Kellgren-Lawrence grading guides treatment decisions, I recommend reading our detailed guide to PRP for knee osteoarthritis.

Why This Guidance Matters

Institutional validation matters in medicine. When a society like AAPM&R issues a formal recommendation, it signals to insurers, referring physicians, and patients that the treatment has crossed a threshold of evidence and clinical acceptance. For PRP, this is a watershed moment.

Prior to this guidance, many patients were told by their orthopedists or primary care doctors that PRP was "experimental" or "not covered." While insurance coverage for PRP remains limited — and this guidance alone will not change that overnight — it provides a powerful tool for advocacy. When a major medical society says a treatment is recommended, it becomes much harder for payers to dismiss it as unproven. I expect we will see gradual movement toward coverage, particularly for patients who meet the specific criteria outlined in the guidance.

Equally important, this guidance gives patients permission to ask for PRP. If you have been told "just wait for a replacement" or "cortisone is your only option," you now have a nationally recognized medical society backing an alternative. Cortisone injections can provide short-term relief, but repeated use may accelerate cartilage loss. PRP, by contrast, aims to modify the underlying disease process by delivering concentrated growth factors to the joint. Multiple meta-analyses have consistently shown that PRP outperforms hyaluronic acid and corticosteroid injections for sustained improvement in pain and function in knee osteoarthritis. The AAPM&R guidance reflects that evidence.

Not All PRP Is the Same

One of the most important points in the new guidance — and one that I emphasize with every patient — is that PRP outcomes are highly dependent on preparation quality. A 2026 study by Hooper and colleagues, published in PM&R, demonstrated that the total deliverable platelet dose is directly associated with clinical outcomes. In other words, more platelets — and more consistent platelet concentration — leads to better results.

This is not a trivial detail. Many clinics use off-the-shelf kits or single-spin systems that produce variable platelet yields. In my practice, I use a double-spin protocol that allows me to control the concentration and volume of the injectate. I also combine PRP with a thorough biomechanical evaluation, because an injection into a joint that is still under abnormal mechanical stress is less likely to succeed. That is why I always incorporate osteopathic manipulative treatment into the treatment plan — to address the underlying joint mechanics that contributed to the osteoarthritis in the first place.

When you read about PRP studies, it is critical to ask: what preparation system was used? What was the platelet count? Was leukocyte content controlled? The AAPM&R guidance acknowledges these variables and calls for standardization in future research. For now, it means that patients should seek out providers who are transparent about their preparation methods and who have experience with PRP for knee osteoarthritis.

What This Means If You Have Knee Osteoarthritis

If you are an active adult in your 30s or 40s with knee pain that limits your ability to run, hike, or play sports, or if you are over 50 and have been told to "learn to live with it," this guidance is directly relevant to you. The recommendation applies to patients with mild to moderate osteoarthritis — the vast majority of people who have knee OA. It does not apply to those with advanced bone-on-bone changes, but for everyone else, PRP is now a recommended option.

In my practice, I see realistic expectations as essential. For patients with Kellgren-Lawrence grades I–III, I typically see a 60–70% meaningful improvement in pain and function, with results that can last 12 to 18 months or longer. PRP is not a cure — osteoarthritis is a chronic condition — but it can delay the need for more invasive interventions like arthroscopy or joint replacement. And because PRP uses your own blood components, the safety profile is excellent, with minimal risk of allergic reaction or infection.

If you are considering PRP, the first step is a proper evaluation. That includes imaging to confirm the grade of osteoarthritis, a physical exam to assess joint stability and alignment, and a discussion of your activity goals. I also assess whether osteopathic manipulative treatment can address any biomechanical contributors to your knee pain. From there, we can determine whether PRP is appropriate for you.

For more information on how PRP is prepared, what the injection experience is like, and how it compares to other treatments, please see our comprehensive guide. And if you have questions about whether you are a candidate, I encourage you to schedule a consultation.